Fluocinolone acetonide intravitreal implant (Iluvien®) is indicated for the prevention of relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||23/11/2020|
|Rapid review completed||21/12/2020|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that fluocinolone acetonide intravitreal implant not be considered for reimbursement at the submitted price*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.